bit.bio articles

bit.bio is featured as a case study of Cambridge Judge Business School`s Accelerate Cambridge mentoring and business development programme. CEO Mark Kotter was part of the programme in 2016.

The feature covers the discovery of our opti-oxTM technology, what our CEO learnt on the programme and what the ambition for the company is. 

bit.bio was featured in Wired after an interview with CEO Mark Kotter and CMO Ramy Ibrahim. They cover our opti-ox™ technology which has the ability to manufacture cells consistently at scale. The piece also explains how cell reprogramming could help develop whole new kinds of treatment such as cell therapy.

bit.bio featured in TechRound`s look forward at 2022.

bit.bio CEO Dr Mark Kotter joined several experts giving their thoughts on what is to come for the health sector in 2022. His focus was on what will happen in the cell therapy space coupled together with synthetic biology approaches.

bit.bio featured in TechRound`s article about startups that have spun out from the University of Cambridge.

Other companies featured include Sano Genetics, Meshed, Cambridge Future Tech and WOAW. 

Izzy Murphy writes about how these businesses were spun out of Cambridge and evolved into the successful companies they are today.

She covers how the idea for bit.bio’s fundamental technology opti-ox&trad

Technology Networks interviews Dr. Mark Kotter, CEO of bit.bio.

The interview digs deep into how bit.bio’s next generation cellular reprogramming technology, opti-ox™, is enabling scientists in research and drug discovery to overcome the shared challenges presented by human muscle models.

Mark explains how pioneering work conducted in the 1980’s sparked the development of opti-ox, and whe